Professor Stephen Gough, MD FRCP (UK)

“Having worked across clinical care, academia and global drug development in diabetes and obesity, I have seen how transformative therapies reach their full potential when patients are supported throughout the treatment journey. Azento Health’s focus on gut health, tolerability, nutrition and long-term metabolic resilience addresses an important need in modern obesity care. The azh-biotics scientific platform brings an evidence-driven microbiome approach to supporting people on modern Anti-Obesity-Medications along their treatment journeys.”

• Professor Stephen Gough, MD FRCP (UK), is Senior Advisor to the World Diabetes Foundation and a former Senior Vice President and Global Chief Medical Officer at Novo Nordisk. He joined Novo Nordisk in 2015 in the Chief Medical Office to provide advice and clinical guidance on the development of new molecules and drugs, from early development through Phase III and beyond. In 2018, he became Senior Vice President and Global Chief Medical Officer, and in 2021 he also became responsible for Global Medical Affairs.
• Before joining Novo Nordisk, Professor Gough was Head of the Oxford Centre for Diabetes, Endocrinology and Metabolism, Professor of Diabetes at the University of Oxford and Consultant Physician at Oxford University Hospitals NHS Trust. His research interests include glucose homeostasis, incretin biology and clinical trials of GLP-1-based therapies.
• He has provided senior medical opinion across diabetes, obesity and biopharma, making his advisory role highly relevant to Azento Health’s focus on obesity care, GLP-1 support, gut health and metabolic disease.